Selection of 3 products from
£0.49 to £1.19
Cimalgex Chewable Tablets are used to treat pain and inflammation caused by osteoarthritis in dogs. They are also of great benefit in the management of pain associated with surgical operations.
For the treatment of surgical pain, the first tablet should be given 2 hours before surgery, then daily for the next 3 to 7 days. For the treatment of osteoarthritis, a daily dose for 6 months or longer can be given. Cimalgex is a safe and effective medication for dogs in the vast majority of situations. However in common with all other similar drugs, it should not normally be given to sick or dehydrated animals, or those suffering from vomiting or diarrhoea.
Cimalgex Chewable Tablets contain cimicoxib which is a non-steroidal anti-inflammatory drug (NSAID). It is a member of the coxib group which act selectively against the enzyme cyclo-oxygenase 2. It is highly selective for the so called COX-2 enzyme, having relatively little effect against the COX-1 form. This provides cimicoxib with a much wider safety margin than many older forms of NSAID.
Cimalgex 8mg chewable tablets for dogs
Cimalgex 30mg chewable tablets for dogs
Cimalgex 80mg chewable tablets for dogs
Oblong, white to pale brown, chewable tablets with a break-line on both sides.
The tablets can be divided into equal halves.
For the treatment of pain and inflammation associated with osteoarthritis, and the management of peri-operative pain due to orthopaedic or soft tissue surgery, in dogs.
Cimalgex tablets can be administered with or without food. The tablets are flavoured and studies (in healthy Beagle dogs) show they are likely to be taken voluntarily by most dogs.
The recommended dose of cimicoxib is 2 mg per kg bodyweight, once daily, according to the dosage table below:
Bodyweight of dog (kg)
Number of Tablets and Tablet Strength
Cimalgex 8 mg
Cimalgex 30 mg
Cimalgex 80 mg
3.0 - 4.0
4.1 - 7.5
7.6 - 15.0
15.1 - 20.0
20.1 - 40.0
40.1 - 60.0
Management of peri-operative pain due to orthopaedic or soft tissue surgeries: one dose 2 hours prior to surgery, followed by 3 to 7 days of treatment, based on the judgment of the attending veterinarian. Relief of pain and inflammation associated with osteoarthritis: 6 months. For longer-term treatment, regular monitoring should be undertaken by the veterinarian.
Do not use in dogs less than 10 weeks of age.
Do not use in dogs suffering from gastrointestinal disorders or haemorrhagic disorders.
Do not use concomitantly with corticosteroids or other non-steroidal anti-inflammatory drugs (NSAIDs).
Do not use in case of hypersensitivity to cimicoxib or to any of the excipients.
Do not use in breeding, pregnant and lactating animals.
Special Warnings: None.
Special precauctions for use in animals:
Since the safety of the medicinal product has not been adequately demonstrated in young animals, careful monitoring is advised during the treatment of young dogs aged less than 6 months.
Use in animals suffering from impaired cardiac or hepatic function, may involve additional risk. If such use cannot be avoided, these animals require careful veterinary monitoring.
Avoid using this product in any animals which are dehydrated, hypovolaemic or hypotensive, as it may increase the risk of renal toxicity.
Use this veterinary medicinal product under strict veterinary monitoring where there is a risk of gastrointestinal ulceration, or if the animal previously displayed intolerance to NSAIDs.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Cimicoxib may cause skin sensitisation. Wash hands after use.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
People with a known hypersensitivity to cimicoxib should avoid contact with the veterinary medicinal product.
Adverse reactions (frequency and seriousness)
Mild and transient gastro-intestinal disorders (vomiting and/or diarrhoea) were very commonly reported.
On rare occasions, serious gastrointestinal disorders such as haemorrhage and ulcer formation have been noted. Other adverse reactions including anorexia or lethargy may also be observed on rare occasions.
In very rare cases, increases in renal biochemistry parameters were noted. As for any long term NSAID treatment, renal function should be monitored.
If any observed adverse effect persists after stopping treatment, the advice of a veterinarian should be sought.
If adverse reactions such as persistent vomiting, repeated diarrhoea, faecal occult blood, sudden weight loss, anorexia, lethargy or worsening of renal or hepatic biochemistry parameters occur, use of the product should be discontinued and appropriate monitoring and/or treatment should be put in place.
Use during pregnancy, lactation or lay
Do not use in breeding, pregnant or lactating bitches. Although no data are available in dogs, studies with laboratory animals have shown effects on their fertility and foetal development.
Interaction with other medicinal products and other forms of interaction
Cimalgex should not be administered in conjunction with corticosteroids or other NSAIDs. Pre-treatment with other anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed before the commencement of treatment with Cimalgex. The treatment-free period should take into account the pharmacokinetic properties of the veterinary medicinal product used previously.
In an overdose study where 3 times (5.8 to 11.8 mg/kg body weight) and 5 times (9.7 to 19.5 mg/kg body weight) the recommended dose was administered to dogs for a period of 6 months, a dose related increase in gastrointestinal disturbances, which affected all dogs in the highest dose group, was noted.
Similar dose related changes to haematology and white blood cell counts, as well as renal integrity, were also noted.
As with any NSAID, overdose may cause gastrointestinal, kidney, or liver toxicity in sensitive or compromised dogs.
There is no specific antidote to this product. Symptomatic, supportive therapy is recommended consisting of administration of gastrointestinal protective agents and infusion of isotonic saline.
Shelf life of the veterinary medicinal product as packaged for sale: 3 years. Any remaining half tablets should be discarded after 2 days storage in the blisters. Any remaining half tablets should be discarded after 90 days storage in the bottle.
This veterinary medicinal product does not require any special storage conditions.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Any half tablets should be stored in the blister pack/bottle.
All strengths are available in the following pack sizes and types: Aluminium blisters (each strip containing 8 tablets) packaged into an outer cardboard box. Pack sizes of 8, 32 or 144 tablets. Plastic (HDPE) bottle (containing 45 tablets) with child resistant plastic (PP) closure packaged into an outer cardboard box.
Cimicoxib is a non-steroidal anti-inflammatory drug belonging to the coxib group and acting by selective inhibition of the enzyme cyclo-oxygenase 2. The cyclo-oxygenase enzyme (COX) is present in two isoforms. COX-1 is usually a constitutive enzyme expressed in tissues, which synthesize products responsible for normal physiologic functions (e.g. in the gastro-intestinal tract and kidneys). COX-2 on the other hand, is mainly inducible and synthesized by macrophages and inflammatory cells after stimulation by cytokines and other mediators of inflammation. COX-2 is involved in the production of mediators, including PGE2, that induce pain, exudation, inflammation and fever.
In an in vivo inflammatory acute pain model, it was shown that the simulated effect of cimicoxib lasted for approximately 10-14 hours.
After oral administration in dogs at the recommended dose of 2 mg/kg without food, cimicoxib is rapidly absorbed and the time to maximal concentration (Tmax) is 2.25 (± 1.24) hours. The peak concentration (Cmax) is 0.3918 (± 0.09021) µg/ml, area under the curve (AUC) is 1.676 (± 0.4735) µg.hr/ml, and oral bioavailability is 44.53 (± 10.26) percent.
The oral administration of cimicoxib with food did not significantly influence the bioavailability but decreased significantly the observed Tmax.
Metabolism of cimicoxib is extensive. The major metabolite, demethylated cimicoxib is mainly eliminated in faeces by the biliary route and, to a lesser extent, in urine. The other metabolite, glucuronide conjugate of the demethylated cimicoxib, is eliminated in urine. The elimination half-life (t1/2) is 1.38 (± 0.24) hours. The metabolising enzymes have not been fully investigated and slower metabolism (up to four-fold increased exposure) has been noted in some individuals.
EU/2/10/119/001 - EU/2/10/119/012
Cimalgex 30mg x 144
Cimalgex 30mg x 32
Cimalgex 80mg x 144
Cimalgex 80mg x 32
Cimalgex 8mg x 144
Cimalgex 8mg x 32
All prices include VAT where applicable.
Below are some recent questions we've received regarding Cimalgex Chewable Tablets for Dogs, including answers from our team.Ask Your Own Question
Sorry that this product is out of stock, instead of having to keep checking back to see if we have it, we can send you a notification as soon as it comes back in stock.
We won't use any details you enter for any other purpose than letting you know when this is back in stock.
Please enter details for each method you'd like us to notify you by:
VioPoints are a way for us to say thank you for purchasing from VioVet.
You will receive VioPoints by purchasing this product, which can be redeemed for a discount on future purchases. For each 1000 points redeemed at the checkout, you will receive a 20p discount.
The number of VioPoints is shown on the product listing and they are awarded on dispatch of the order.
Terms and conditions apply.